Immunome (IMNM) Short-term Investments (2023 - 2025)

Immunome's Short-term Investments history runs 3 years deep, the most recent figure standing at $124.2 million for Q2 2025.

• Quarterly Short-term Investments rose 9.91% year-over-year to $124.2 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $124.2 million (up 9.91% YoY) and the FY2024 annual result came in at $74.0 million, up 87.4% from the prior year.
• Short-term Investments was $124.2 million for Q2 2025 at Immunome, up from $59.7 million in the prior quarter.
• Across five years, Short-term Investments topped out at $124.2 million in Q2 2025 and bottomed at $39.5 million in Q4 2023.
• A 3-year average of $76.4 million and a median of $74.0 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2024 — Short-term Investments soared 87.4% — and 2025, when it rose 9.91%.
• Immunome's Short-term Investments stood at $39.5 million in 2023, then jumped by 87.4% to $74.0 million in 2024, then surged by 67.95% to $124.2 million in 2025.
• Business Quant data shows IMNM's Short-term Investments at $124.2 million in Q2 2025, $59.7 million in Q1 2025, and $74.0 million in Q4 2024.